Vizsgálati helyszín
Hopital Larrey
Toulouse, 31059, FranciaországMég nincs intézményhez kötve
- 16futó vizsgálat
- 14lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 30 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis7 vizsgálat
- 2. fázis3 vizsgálat
- 2/3. fázis2 vizsgálat
- 1. fázis1 vizsgálat
- 1/2. fázis1 vizsgálat
- Állapot
- Lezárult13 vizsgálat
- Toboroz8 vizsgálat
- Fut, nem toboroz5 vizsgálat
- Még nem toboroz2 vizsgálat
- Meghívásos bevonás1 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- Eli Lilly and Company2 vizsgálat
- Groupe Francais De Pneumo-Cancerologie2 vizsgálat
- Hoffmann-La Roche2 vizsgálat
- Institut Claudius Regaud2 vizsgálat
- Pfizer2 vizsgálat
- és még 20
Futó vizsgálatok
Még nem toboroz
Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary Angioplasty
NCT07644377· 3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Contact: Elise NOEL SAVINA, MD
Toboroz
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· 3. fázis· ArriVent BioPharma, Inc.· Forrás
Contact: Clinical Trials
Toboroz
Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)
NCT07243132· GFPC Investigation· Forrás
Contact: Laurence BIGAY-GAME
Toboroz
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
NCT06701513· Bristol-Myers Squibb· Forrás
Contact: MAELLA SEVERINO FREIRE, Site 037
Toboroz
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245· 3. fázis· OSE Immunotherapeutics· Forrás
Contact: Caroline Chevalier, MSc, MPH
Fut, nem toboroz
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109· Pfizer· Forrás
Toboroz
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
NCT05689151· Pfizer· Forrás
Fut, nem toboroz
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565· 2/3. fázis· Biogen· Forrás
Meghívásos bevonás
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT04905693· 3. fázis· United Therapeutics· Forrás
Fut, nem toboroz
Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome
NCT05382156· RECORDATI GROUP· Forrás
Toboroz
Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
NCT05122806· Groupe Francais De Pneumo-Cancerologie· Forrás
Contact: Laurence BIGAY-GAME
Toboroz
Deciphering Mechanisms Underlying Cancer Immunogenicity
NCT03958240· Institut Claudius Regaud· Forrás
Contact: Julien MAZIERES
Fut, nem toboroz
Evaluation of the Safety and Efficacy of TLD in Patients with COPD
NCT03639051· Nuvaira, Inc.· Forrás
Toboroz
PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer
2024-512173-27-00· 3. fázis· Unicancer· Forrás
Toboroz
FARD (RaDiCo Cohort) (RaDiCo-FARD)
NCT05954416· Institut National de la Santé Et de la Recherche Médicale, France· Forrás
Contact: Juliette MAZEREEUW-HAUTIER
Fut, nem toboroz
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
NCT02779751· 1. fázis· Eli Lilly and Company· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
Performances and Safety of MuCopilot, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis
NCT06147778· Ad scientiam· Forrás
Lezárult
Impact of Circadian Rhythm on the Spread of Circulating Tumor Cells in Lung Cancer Patients
NCT05988970· Institut Claudius Regaud· Forrás
Leállították
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260· 2. fázis· Pliant Therapeutics, Inc.· Forrás
Lezárult
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
NCT05322096· 2. fázis· Gedeon Richter Plc.· Forrás
Lezárult
Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
NCT05308966· Groupe Francais De Pneumo-Cancerologie· Forrás
Lezárult
Zephyr Etude Post-Inscription (French Registry)
NCT04517916· Pulmonx Corporation· Forrás
Lezárult
Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation
NCT04233021· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Lezárult
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
NCT04392154· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT04129502· 3. fázis· Takeda· Forrás
Lezárult
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
NCT04010253· Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche· Forrás
Lezárult
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
NCT03782207· Hoffmann-La Roche· Forrás
Lezárult
Quality of Sleep of Patients With Predominant Central Sleep Apnea Syndrome(SAS) Whose EF > 45% Treated by ASV
NCT02835638· Société Française de Recherche et de Médecine du Sommeil· Forrás
Lezárult
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
NCT03037385· 1/2. fázis· Hoffmann-La Roche· Forrás
Lezárult
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
NCT02784171· 2/3. fázis· Canadian Cancer Trials Group· Forrás
Hibát jelzek